Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06499857 · ClinicalTrials.gov registry record · Phase 3
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation and Overweight or Obesity, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 200
- Enrollment target
- 2
- Study locations
NCT06499857 is a Phase 3 study of Atrial Fibrillation and Overweight or Obesity that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 200 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06499857, a Phase 3 study of Atrial Fibrillation and Overweight or Obesity, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 200 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (2)
Arizona
- The University of Arizona College of Medicine- Phoenix - Phoenix
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06499857
The ClinicalTrials.gov registry entry for NCT06499857 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06499857 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, Illinois.
Frequently Asked Questions
What is clinical trial NCT06499857 about?
NCT06499857 is a clinical study titled "Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation". The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.
What is the current status of trial NCT06499857?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 200 participants. The study started on 2025-04-14. Estimated completion is 2028-06.
What conditions does trial NCT06499857 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Overweight or Obesity.
What interventions are being tested in trial NCT06499857?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06499857?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06499857 being conducted?
This trial has 2 study locations across Arizona, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
-
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.